Conversion to dementia in mild cognitive impairment is associated with decline of N-actylaspartate and creatine as revealed by magnetic resonance spectroscopy
暂无分享,去创建一个
Heinrich Lanfermann | Friedhelm E. Zanella | Konrad Maurer | Johannes Pantel | Lutz Frölich | Ulrich Pilatus | J. Pantel | H. Lanfermann | F. Zanella | L. Frölich | K. Maurer | U. Pilatus | Christoph Lais | Anna du Mesnil de Rochmont | Tillmann Kratzsch | C. Lais | T. Kratzsch
[1] Peter Schönknecht,et al. Prevalence and natural course of aging-associated cognitive decline in a population-based sample of young-old subjects. , 2005, The American journal of psychiatry.
[2] F. Jessen,et al. Decrease of N-acetylaspartate in the MTL correlates with cognitive decline of AD patients , 2001, Neurology.
[3] D. Auer,et al. Hippocampal metabolic abnormalities in mild cognitive impairment and Alzheimer's disease , 2005, Neuroscience Letters.
[4] P. Renshaw,et al. Brain proton magnetic resonance spectroscopy in Alzheimer disease: changes after treatment with xanomeline. , 2002, The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry.
[5] F. Jessen,et al. Treatment monitoring and response prediction with proton MR spectroscopy in AD , 2006, Neurology.
[6] S. Chantal,et al. Similar 1H magnetic resonance spectroscopic metabolic pattern in the medial temporal lobes of patients with mild cognitive impairment and Alzheimer disease , 2004, Brain Research.
[7] M. Essig,et al. Parahippocampal volume deficits in subjects with aging-associated cognitive decline. , 2003, The American journal of psychiatry.
[8] S. Folstein,et al. "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. , 1975, Journal of psychiatric research.
[9] Kevin M Bradley,et al. Longitudinal quantitative proton magnetic resonance spectroscopy of the hippocampus in Alzheimer's disease. , 2002, Brain : a journal of neurology.
[10] Patrizia Mecocci,et al. Conversion of MCI to dementia: Role of proton magnetic resonance spectroscopy , 2006, Neurobiology of Aging.
[11] M. Viitanen,et al. Voxel-based analysis of PET amyloid ligand [11C]PIB uptake in Alzheimer disease , 2006, Neurology.
[12] Clifford R. Jack,et al. Longitudinal 1H MRS changes in mild cognitive impairment and Alzheimer's disease , 2007, Neurobiology of Aging.
[13] O Henriksen,et al. In vivo quantitation of metabolite concentrations in the brain by means of proton MRS , 1995, NMR in biomedicine.
[14] Roland Kreis,et al. Development of the human brain: In vivo quantification of metabolite and water content with proton magnetic resonance spectroscopy , 1993, Magnetic resonance in medicine.
[15] E. Sullivan,et al. Longitudinal decline of the neuronal marker N-acetyl aspartate in Alzheimer's disease , 2000, The Lancet.
[16] C. Jack,et al. Mild cognitive impairment – beyond controversies, towards a consensus: report of the International Working Group on Mild Cognitive Impairment , 2004, Journal of internal medicine.
[17] E G Tangalos,et al. Regional metabolic patterns in mild cognitive impairment and Alzheimer’s disease , 2000, Neurology.
[18] J. Frahm,et al. Absolute concentrations of metabolites in the adult human brain in vivo: quantification of localized proton MR spectra. , 1993, Radiology.
[19] P Sachdev,et al. Magnetic resonance spectroscopy in AD , 2001, Neurology.
[20] S. Provencher. Estimation of metabolite concentrations from localized in vivo proton NMR spectra , 1993, Magnetic resonance in medicine.
[21] N. Butters,et al. The Consortium to Establish a Registry for Alzheimer's Disease (CERAD). Part V. A normative study of the neuropsychological battery , 1994, Neurology.
[22] Giuseppe Scotti,et al. A whole brain MR spectroscopy study from patients with Alzheimer's disease and mild cognitive impairment , 2005, NeuroImage.
[23] Clifford R Jack,et al. 1H magnetic resonance spectroscopy, cognitive function, and apolipoprotein E genotype in normal aging, mild cognitive impairment and Alzheimer's disease , 2002, Journal of the International Neuropsychological Society.
[24] P. Sundgren,et al. Magnetic resonance spectroscopy. , 2005, Journal of neuro-ophthalmology : the official journal of the North American Neuro-Ophthalmology Society.
[25] N. Schuff,et al. Headache and cerebral venous air embolism , 2007, Neurology.
[26] U Senin,et al. 1H-MR spectroscopy differentiates mild cognitive impairment from normal brain aging , 2001, Neuroreport.
[27] R. Mohs,et al. Consortium to establish a registry for Alzheimer's disease (CERAD) clinical and neuropsychological assessment of Alzheimer's disease. , 2002, Psychopharmacology bulletin.
[28] B. L. Miller,et al. Reduced medial temporal lobe N-acetylaspartate in cognitively impaired but nondemented patients , 2005, Neurology.
[29] L R Schad,et al. Quantitative magnetic resonance imaging and neuropsychological functions in dementia of the Alzheimer type , 1997, Psychological Medicine.
[30] N. Fayed,et al. Conversion from mild cognitive impairment to probable Alzheimer's disease predicted by brain magnetic resonance spectroscopy. , 2005, The American journal of psychiatry.
[31] C. Jack,et al. Proton MR spectroscopy in mild cognitive impairment and Alzheimer disease: comparison of 1.5 and 3 T. , 2003, AJNR. American journal of neuroradiology.